These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8036 related articles for article (PubMed ID: 18540532)

  • 21. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
    Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Updates on immunotherapy in non-small cell lung cancer.
    Shimanovsky A; Dasanu CA
    Expert Opin Biol Ther; 2014 Apr; 14(4):411-8. PubMed ID: 24512518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MAGE A3 antigen-specific cancer immunotherapeutic.
    Peled N; Oton AB; Hirsch FR; Bunn P
    Immunotherapy; 2009 Jan; 1(1):19-25. PubMed ID: 20635969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Belagenpumatucel-L for the treatment of non-small cell lung cancer.
    Rijavec E; Biello F; Genova C; Barletta G; Maggioni C; Dal Bello MG; Coco S; Truini A; Vanni I; Alama A; Beltramini S; Grassi MA; Boccardo F; Grossi F
    Expert Opin Biol Ther; 2015; 15(9):1371-9. PubMed ID: 26211534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic Cell-Based Immunotherapy in Lung Cancer.
    Stevens D; Ingels J; Van Lint S; Vandekerckhove B; Vermaelen K
    Front Immunol; 2020; 11():620374. PubMed ID: 33679709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What lies within: novel strategies in immunotherapy for non-small cell lung cancer.
    Forde PM; Reiss KA; Zeidan AM; Brahmer JR
    Oncologist; 2013; 18(11):1203-13. PubMed ID: 24105749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development.
    Decoster L; Wauters I; Vansteenkiste JF
    Ann Oncol; 2012 Jun; 23(6):1387-93. PubMed ID: 22156658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy for lung cancer.
    Bradbury PA; Shepherd FA
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S164-70. PubMed ID: 18520304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Present and future of lung cancer vaccines.
    Raez LE; Rosenblatt JD; Podack ER
    Expert Opin Emerg Drugs; 2006 Sep; 11(3):445-59. PubMed ID: 16939384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
    Anagnostou VK; Brahmer JR
    Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for lung cancer: ongoing clinical trials.
    Declerck S; Vansteenkiste J
    Future Oncol; 2014 Jan; 10(1):91-105. PubMed ID: 24143916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality.
    Kelly RJ; Gulley JL; Giaccone G
    Clin Lung Cancer; 2010 Jul; 11(4):228-37. PubMed ID: 20630824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immune alterations in lung cancer - the new therapeutic approach].
    Domagała-Kulawik J; Osińska I
    Pneumonol Alergol Pol; 2014; 82(3):286-99. PubMed ID: 24793154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Vaccines for the treatment of non-small cell lung cancer].
    Leduc C; Quoix E
    Rev Mal Respir; 2019 Mar; 36(3):415-425. PubMed ID: 30902445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells.
    Srivastava MK; Bosch JJ; Wilson AL; Edelman MJ; Ostrand-Rosenberg S
    Int J Cancer; 2010 Dec; 127(11):2612-21. PubMed ID: 20473949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The current therapeutic cancer vaccines landscape in non-small cell lung cancer.
    Chen S; Cheng S; Cai J; Liu Z; Li H; Wang P; Li Y; Yang F; Chen K; Qiu M
    Int J Cancer; 2024 Dec; 155(11):1909-1927. PubMed ID: 39109825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot study of 1650-G: a simplified cellular vaccine for lung cancer.
    Hirschowitz EA; Mullins A; Prajapati D; Baeker T; Kloecker G; Foody T; Damron K; Love C; Yannelli JR
    J Thorac Oncol; 2011 Jan; 6(1):169-73. PubMed ID: 21150468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer.
    Adam V; Wauters I; Vansteenkiste J
    Expert Opin Biol Ther; 2014 Mar; 14(3):365-76. PubMed ID: 24456101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 402.